Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Accumulated Expenses (2019 - 2025)

BridgeBio Pharma's Other Accumulated Expenses history spans 7 years, with the latest figure at $120.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 263.53% year-over-year to $120.2 million; the TTM value through Dec 2025 reached $120.2 million, up 263.53%, while the annual FY2025 figure was $120.2 million, 263.53% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $120.2 million at BridgeBio Pharma, up from $92.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $120.2 million in Q4 2025 and bottomed at $4.7 million in Q4 2023.
  • The 5-year median for Other Accumulated Expenses is $18.3 million (2021), against an average of $26.3 million.
  • The largest annual shift saw Other Accumulated Expenses surged 81055.56% in 2021 before it tumbled 82.86% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $30.3 million in 2021, then crashed by 82.86% to $5.2 million in 2022, then decreased by 10.27% to $4.7 million in 2023, then surged by 610.14% to $33.1 million in 2024, then surged by 263.53% to $120.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other Accumulated Expenses are $120.2 million (Q4 2025), $92.7 million (Q3 2025), and $4.7 million (Q2 2025).